Iradimed Shares Outstanding History (IRMD)
Iradimed reported 12.8M shares outstanding at the end of fiscal 2025.
View full Iradimed company overviewIradimed annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 12.8M | 71,914 | +0.57% |
| 2024 | 2024-12-31 | 12.7M | 49,547 | +0.39% |
| 2023 | 2023-12-31 | 12.7M | 69,309 | +0.55% |
| 2022 | 2022-12-31 | 12.6M | 46,980 | +0.37% |
| 2021 | 2021-12-31 | 12.5M | 235,592 | +1.91% |
| 2020 | 2020-12-31 | 12.3M | 542,557 | +4.61% |
| 2019 | 2019-12-31 | 11.8M | 776,764 | +7.07% |
| 2018 | 2018-12-31 | 11.0M | 392,545 | +3.70% |
| 2017 | 2017-12-31 | 10.6M | −126,109 | −1.18% |
| 2016 | 2016-12-31 | 10.7M | −452,450 | −4.05% |
| 2015 | 2015-12-31 | 11.2M | −7.8M | −40.95% |
| 2014 | 2014-12-31 | 18.9M | −96.0M | −83.53% |
| 2013 | 2013-12-31 | 114.9M | — | — |
Iradimed quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 12.8M | 66,738 | +0.52% |
| Q1 2026 | 2026-03-31 | 12.8M | 67,728 | +0.53% |
| Q4 2025 | 2025-12-31 | 12.8M | 71,914 | +0.57% |
| Q3 2025 | 2025-09-30 | 12.7M | 51,244 | +0.40% |
| Q2 2025 | 2025-06-30 | 12.7M | 50,901 | +0.40% |
| Q1 2025 | 2025-03-31 | 12.7M | 50,924 | +0.40% |
| Q4 2024 | 2024-12-31 | 12.7M | 49,547 | +0.39% |
| Q3 2024 | 2024-09-30 | 12.7M | 67,061 | +0.53% |
| Q2 2024 | 2024-06-30 | 12.7M | 74,525 | +0.59% |
| Q1 2024 | 2024-03-31 | 12.7M | 73,181 | +0.58% |
| Q4 2023 | 2023-12-31 | 12.7M | 99,288 | +0.79% |
| Q3 2023 | 2023-09-30 | 12.6M | 41,826 | +0.33% |
| Q1 2023 | 2023-03-31 | 12.6M | 34,107 | +0.27% |
| Q4 2022 | 2022-12-31 | 12.6M | 46,980 | +0.37% |
| Q3 2022 | 2022-09-30 | 12.6M | 220,371 | +1.79% |
| Q2 2022 | 2022-06-30 | 12.6M | 243,989 | +1.98% |
| Q1 2022 | 2022-03-31 | 12.6M | 248,285 | +2.02% |
| Q4 2021 | 2021-12-31 | 12.5M | 235,592 | +1.91% |
| Q3 2021 | 2021-09-30 | 12.3M | 71,531 | +0.58% |
| Q2 2021 | 2021-06-30 | 12.3M | 119,199 | +0.98% |
| Q1 2021 | 2021-03-31 | 12.3M | 341,247 | +2.85% |
| Q4 2020 | 2020-12-31 | 12.3M | 542,557 | +4.61% |
| Q3 2020 | 2020-09-30 | 12.3M | 837,656 | +7.33% |
| Q2 2020 | 2020-06-30 | 12.2M | 1.0M | +8.94% |
| Q1 2020 | 2020-03-31 | 12.0M | 826,741 | +7.42% |
| Q4 2019 | 2019-12-31 | 11.8M | 776,764 | +7.07% |
| Q3 2019 | 2019-09-30 | 11.4M | 497,478 | +4.55% |
| Q2 2019 | 2019-06-30 | 11.2M | 530,484 | +4.97% |
| Q1 2019 | 2019-03-31 | 11.1M | 522,154 | +4.92% |
| Q4 2018 | 2018-12-31 | 11.0M | 392,545 | +3.70% |
| Q3 2018 | 2018-09-30 | 10.9M | 379,236 | +3.59% |
| Q2 2018 | 2018-06-30 | 10.7M | 83,950 | +0.79% |
| Q1 2018 | 2018-03-31 | 10.6M | −127,853 | −1.19% |
| Q4 2017 | 2017-12-31 | 10.6M | −126,109 | −1.18% |
| Q3 2017 | 2017-09-30 | 10.6M | −8.2M | −43.70% |
| Q2 2017 | 2017-06-30 | 10.6M | −8.1M | −43.32% |
| Q1 2017 | 2017-03-31 | 10.7M | −8.4M | −43.72% |
| Q4 2016 | 2016-12-31 | 10.7M | −8.8M | −45.17% |
| Q3 2016 | 2016-09-30 | 18.7M | −15.2M | −44.70% |
| Q2 2016 | 2016-06-30 | 18.7M | −40.2M | −68.26% |
| Q1 2016 | 2016-03-31 | 19.1M | −83.8M | −81.44% |
| Q4 2015 | 2015-12-31 | 19.6M | −81.9M | −80.72% |
| Q3 2015 | 2015-09-30 | 33.9M | −142.0M | −80.73% |
| Q2 2015 | 2015-06-30 | 58.8M | −142.2M | −70.74% |
| Q1 2015 | 2015-03-31 | 102.9M | −12.0M | −10.42% |
| Q4 2014 | 2014-12-31 | 101.4M | — | — |
| Q3 2014 | 2014-09-30 | 175.9M | — | — |
| Q2 2014 | 2014-06-30 | 201.1M | — | — |
| Q4 2013 | 2013-12-31 | 114.9M | — | — |
Iradimed shares outstanding trends
Over the last five reported fiscal years, Iradimed's shares outstanding moved from 12.3M to 12.8M, a change of 473,342. The latest reported quarter, Q2 2026, shows 12.8M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Iradimed filings at SEC.gov ↗